Market Intelligence, Clinical Progress, and High-Purity Reagents for Cholangiocarcinoma, Gastric, and Endometrial Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for FGFR2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Isoform IIIb) | FGFR2 (IIIb)-ECD-Fc Fusion Protein HEK293 Expressed, Native Glycosylation, High Purity (>95%), Endotoxin <1EU/µg. Sequence Verified. |
View FGFR2 Products |
| Antigen (Isoform IIIc) | FGFR2 (IIIc)-ECD-Fc Fusion Protein Mesenchymal isoform for fusion-positive cancer models. Theoretical MW verified. |
View FGFR2 Products |
| Gene Delivery | FGFR2 Promise-ORF / Lentivirus Premade Particles Full-length wild-type and N550K gatekeeper mutant. For stable BaF3 or CHO cell line construction. |
View FGFR2 Products |
| Mutant Panel | FGFR2 Kinase Domain Mutants (G565A, N550K, V565I) Recombinant proteins for acquired resistance screening. Sequence Verified. |
View FGFR2 Products |
| Benchmark Ab | Anti-FGFR2 (Bemarituzumab biosimilar sequence) Recombinant positive control for internalization assays. |
View FGFR2 Products |
| Validator | FGFR2 siRNA Set (3 target-specific duplexes) For knockdown verification and specificity controls. |
View FGFR2 Products |
| Related Target: FGFR1 | FGFR1/CD331 Paralog receptor for selectivity counter-screening (avoid hyperphosphatemia). |
View FGFR1 Products |
| Related Target: FGFR3 | FGFR3/CD333 Frequent co-alteration in urothelial and endometrial cancers. Combination potential. |
View FGFR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform IIIb vs IIIc selectivity (Epithelial vs Mesenchymal) | Distinct ECD-Fc constructs for each splice variant (IIIb: AA 22-377; IIIc: AA 22-377 with alternative C-terminal domain), Sequence Verified by Mass Spec. |
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno ortholog FGFR2-ECD proteins available with >95% purity, Endotoxin controlled for in vivo surrogate assessment. |
| Subfamily selectivity (vs FGFR1/3/4) | Homolog panel proteins (FGFR1, FGFR3, FGFR4 ECD-Fc) strictly verified by mass spec for binding specificity assays. |
| ADC Internalization Efficiency | Full-length FGFR2 Lentivirus for stable CHO/K562 cell lines. Preserves native conformation for pH-dependent uptake assays. |
| Acquired Resistance Mutations | Gatekeeper (N550K) and activation loop mutants available as recombinant proteins and lentivirus for cell-based resistance modeling. |
| Lack of Controls | Clinical Benchmark Antibodies (Bemarituzumab biosimilar) included for assay standardization. |
Live FGFR2/CD332 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The FGFR2 therapeutic landscape has transitioned from pan-FGFR small molecule inhibitors (Pemigatinib, Infigratinib, Futibatinib) to next-generation biologics targeting specific isoforms and minimizing FGFR1-related on-target toxicity. Anti-FGFR2b monoclonal antibodies have demonstrated clinically meaningful efficacy in gastric cancer, while isoform-selective ADCs (particularly FGFR2c/IIIc-targeting) are emerging for cholangiocarcinoma and gastric cancer. As first-generation therapies face acquired resistance (gatekeeper mutations such as N550K), the next wave of R&D focuses on mutant-selective inhibitors and antibody-based modalities with improved therapeutic indices.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Isoform-Selective ADC | AstraZeneca (AZD9592), Others | Cholangiocarcinoma, Gastric (FGFR2b/2c high) | Internalization Assay (Need high-purity IIIb vs IIIc ECD-Fc for isoform-specific binding); pH-dependent release validation. |
| Monoclonal Antibody | Amgen (Bemarituzumab - approved in Japan), Five Prime (acquired) | Gastric Cancer (FGFR2b overexpression) | Fc-effector function assays; Cross-species reactivity (Cyno/Mouse) for toxicology bridging. |
| Small Molecule Inhibitor (Selective) | Relay Therapeutics (RLY-4008), Taiho (Futibatinib) | Cholangiocarcinoma, Solid Tumors with fusions | Kinase selectivity panel (FGFR1/2/3/4 vs mutant panel); Gatekeeper mutation (N550K) screening. |
| Bispecific (FGFR2 x CD3) | Preclinical/Undisclosed | Solid Tumors | Heterodimer validation; T-cell engagement assays using full-length FGFR2 cell lines. |